by ZPHC
Tirze 75mg dual-chamber auto-mixing pen by ZPHC. Long-term supply.
In stock
Pay with Bitcoin or USDT (TRC-20) on this site, or contact a representative for a card or bank payment link. Free EU shipping over €250.
Batch certificate of analysis available on request via Telegram or the contact form.
ZPHC Tirzepatide 75mg Dual Cartridge Pen is the highest-supply tirzepatide format available, containing 75mg in a dual-chamber auto-mixing system that keeps lyophilized peptide and diluent separate until first activation — ensuring maximum stability throughout the pen's use period. The 75mg supply supports extended single-subject protocols (approximately 5–37 weeks at 2–15mg weekly doses) or comparative multi-subject studies. Tirzepatide's dual GIP/GLP-1 agonism underlies the Phase 3 SURMOUNT-1 20.9% weight reduction outcome.
EU stock, ZPHC GMP-grade production, Janoshik-verified 99%+ purity. For laboratory research use only.
Peptides & Recovery
Semaglutide-based metabolic research protocols use diet-induced obesity (DIO) rodent models to study GLP-1R-mediated weight loss, glycemic improvement, and lipid remodeling. Guide to the semaglutide DIO research stack — compound selection, protocol design, dose escalation, and endpoints.
4 min read
Weight Loss & GLP-1
Semaglutide, retatrutide, and tirzepatide represent three generations of incretin-based therapy with distinct receptor targets. Research comparison of mechanisms, clinical trial weight loss data, receptor pharmacology, and research applications for each compound class.
4 min read
Weight Loss & GLP-1
Head-to-head comparison of retatrutide (triple GIP/GLP-1/glucagon agonist) vs tirzepatide (dual GIP/GLP-1). Phase 2 and Phase 3 data, mechanism differences, and what the research says about each.
9 min read
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Must be handled by qualified professionals in a controlled laboratory setting. JuicedPharma makes no therapeutic or medical claims about this compound.
Hilma Biocare
GLP-1 receptor agonist. The active compound in Ozempic/Wegovy research.
99.0%· Janoshik
Hilma Biocare
Pre-filled semaglutide pen. Convenient auto-injector for research use.
99.0%· Janoshik
Pharmacom Labs
Pharmacom T3 liothyronine. 50mcg double-strength tablets.
99%+· Pharmacom
Pharmacom Labs
Sibutramine 15mg double-strength tablets. Central appetite research.
99%+· Pharmacom
Resellers, laboratories and publishers: apply for partner pricing, volume terms and a dedicated representative.
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Products sold by JuicedPharma are not medicines. By ordering you confirm you are a qualified person buying for research in compliance with applicable regulations. Full disclaimer